Dimensional Global ex US Core Fixed Income ETF (DFGX) News

Form 8-K - Current report

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival...

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical...

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical...

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical...

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

- Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor...

Form 424B5 - Prospectus [Rule 424(b)(5)]

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical...

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical...

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical...

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

- Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells...

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100...